HHS Peptide Policy: Small Pharmacies Gain Limited Production Rights

The Department of Health and Human Services announced a new policy on Tuesday that will allow small compounding pharmacies to manufacture six popular wellness peptides. The agency stated it will exercise enforcement discretion for these substances, effectively permitting their production without immediate federal penalty. This move formalizes a path for 503A facilities to make peptides that previously existed primarily on the gray market.

The policy specifically targets smaller producers, known as 503A compounding pharmacies. It does not apply to larger outsourcing facilities, or 503Bs, which produce higher volumes of medicine. Health Secretary Robert F. Kennedy Jr. has been a vocal advocate for peptides, noting that he has used some of them personally. The administration argues that regulated compounding is safer than the illicit research-use-only peptides currently sold online by overseas suppliers.

The six peptides included in the policy are BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Proponents have promoted these amino acid chains for uses ranging from ulcerative colitis and insomnia to wound healing and metabolic health. However, none of these substances have completed the Food and Drug Administration's rigorous drug review and approval process. Evidence for their safety and effectiveness remains sparse.

Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, said his company has received years of customer inquiries about the peptides. Because they were previously illegal to compound, his firm did not produce them. Under the new rules, only his smaller facility can make the products, and only in limited quantities. Fritzler stated that his company will likely focus on just one of the six peptides and that he does not believe all 503A pharmacies in the country can meet existing demand.

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, called the decision a more accountable alternative for patients. He noted that the policy brings these products into a system with pharmacy standards and adverse event reporting. However, he warned that it may take time for pharmacies to begin dispensing the drugs. Ingredient suppliers must verify that their active components meet the new requirements before production can start.

Critics argue the policy bypasses standard regulatory procedures. Dr. Robert Steinbrook, health research group director at Public Citizen, wrote that Kennedy acted unilaterally rather than through typical rulemaking. He stated that allowing unproven peptides to be marketed without concern for federal enforcement undermines the FDA. Shabbir Safda, executive director of the Partnership for Safe Medicines, noted that the FDA’s own scientists recommended against expanding access to these substances in July due to evidence concerns.

The Partnership for Safe Medicines filed a citizen petition with the FDA last week, urging the agency to ignore the July advisory committee's recommendation. The group includes various pharmacy and pharmacist organizations. The new HHS policy leaves the legal status of the peptides unchanged, but it creates a specific operational path for small compounding facilities to enter the market.